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ABSTRACT 
IMMUNOLOGIC INFERTILITY 
AND IN VITRO FERTILIZATION/EMBRYO TRANSFER (IVF/ET): 
THE CLINICAL SIGNIFICANCE OF ANTISPERM ANTIBODIES 
Stacey Lee Mandelbaum 
1986 
Antisperm antibodies are believed to impair repro¬ 
duction and have been detected in infertile couples, 
particularly those whose infertility is unexplained. An 
unselected infertile population undergoing IVF/ET was 
studied. The semen, serum and follicular fluid of 40 
couples who underwent IVF/ET between August and October 1985 
at Yale-New Haven Hospital were tested with the immunobead 
binding assay to identify antisperm antibodies of IgA, IgG 
and IgM isotypes, directed to sperm head, tail and tail tip. 
Antibody binding to sperm tail tip did not affect 
fertilization. Antibodies to sperm head in female serum 
reduced the oocyte fertilization rate significantly from 71% 
to 31% (p<0.001). Antibodies to sperm head in female serum 
also reduced the zygote cleavage rate from 91% to 67% 
(p=0.051). Serum antibodies to sperm head were present in 
60% of women in whom no ova fertilized (n=5), compared to 6% 
of women whose ova did fertilize (n=35; p<0.05). The oocyte 
fertilization rate was also lower in women with antibodies 
to sperm head in follicular fluid (29%) than in those 
without these antibodies (66%; N.S.). Analysis of single 
antisperm antibody isotypes was not as useful as the use of 

all isotypes combined in predicting fertilization. Fifty- 
five percent (n=ll) of the couples with unexplained 
infertility had antibodies to sperm head in one or more 
fluid tested, compared to an 8% incidence in couples with 
tubal infertility (n=25; p=0„005). In summary, 1) clini¬ 
cally significant antibodies to sperm were present in an 
unselected IVF/ET population, particularly in those patients 
whose infertility was unexplained; 2) the presence of 
antibodies to sperm head in female serum significantly 
reduced fertilization rate. 

INTRODUCTION 
3 
Approximately 10% of couples who desire pregnancy are 
infertile.! For most infertile couples, medical investiga¬ 
tion detects an abnormality in one or both partners which 
accounts for infertility. However, in 10-20% of infertile 
-couples, the investigation reveals a normal semen analysis 
in the man and regular ovulation, a normal uterine cavity 
and patent fallopian tubes without peri-tubal adhesions or 
endometriosis in the woman.2»3 If these couples have been 
having regular unprotected sexual intercourse for at least 
two years and no cause for infertility is found, their 
is described as "unexplained 
Immunologic factors are probably responsible for a 
number of cases of unexplained infertility. More than 20 
years ago, Franklin and Dukes^ reported finding antisperm 
antibodies in 79% of women with unexplained infertility. 
Recent studies with newer methods have shown a somewhat 
lower incidence of antisperm antibodies in unexplained 
infertility. Antisperm antibodies were detected in the 
semen of 21% of men with otherwise unexplained inferti1ity . 5 
Circulating antisperm antibodies were found in 13% of women 
and 7% of men with otherwise unexplained infertility.^ In 
general, immunologic factors play a significant role in the 
pathogenesis of approximately 10-20% of unexplained inferti¬ 
lity .^,8,9,10 
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The chance of conception has been shown to be signifi¬ 
cantly decreased in couples with antisperm antibodies. In 
couples where antibody binding of >50% of the sperm in the 
man's ejaculate was the only known cause of infertility, the 
pregnancy rate without treatment was 15%, as compared with a 
67% conception rate of infertile men with <50% of their 
.sperm bound „ 1 1 Among women with unexplained or minor 
organic infertility of three or more years duration, the 
pregnancy rate without treatment was 13% in those with 
circulating antisperm antibodies and 45% in those without. 
Clearly, current investigations must identify clinically 
significant antibodies to sperm and develop effective 
therapies against them. 
Spontaneously-occurring antibodies to sperm were first 
detected by Rumke and Hellinga (1959)12 in infertile men. 
Since then, a number of methods to detect antisperm antibod¬ 
ies have been developed. However, most of these have gained 
only qualified acceptance because they have failed to 
reliably measure clinically significant antibodies to 
sperm.7,8,13,14,15,16 Bronson et a 1 1 2 have recently 
described an immunobead binding assay to detect antibodies 
to sperm in serum, semen and other reproductive fluids. The 
assay detects immunoglobulin bound to the surface of living 
sperm and identifies the region of antibody binding, the 
isotype of immunoglobulin bound, and the extent of binding. 
Use of the assay has been reported by only two groups^,18 
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and is in its infancy. In early studies by Bronson's 
group,11>19,20 the assay has been shown to identify clini¬ 
cally significant antisperm antibodies. 
Why test for antibodies to sperm in an In Vitro 
Fertilization/Embryo Transfer (IVF/ET) population7 IVF/ET, 
which is most often used to treat patients with tubal 
infertility, is also being used empirically to treat 
patients with immunologic inferti1ity21,22,23,24,25,26 and 
patients with unexplained i n f e r t i 1 i t y , 2 7 who are at risk for 
immunologic infertility but may not have been tested for 
antibodies to sperm. There are no published data on the 
incidence of antibodies to sperm in an unselected infertile 
population undergoing IVF/ET. In addition to incidence, 
studying an unselected IVF/ET population would define the 
clinical and prognostic significance of these antibodies. 
It would indicate the therapeutic value of the IVF/ET 
process for these patients and might provide the opportunity 
to tailor IVF/ET methods to maximize the chance of concep¬ 
tion for these patients in the future. Moreover, results of 
IVF outcome in these patients provide a direct opportunity 
to evaluate the effects of antibodies to sperm on human 
fertilization, cleavage and conception in IVF/ET. 
In this study, infertile couples undergoing IVF/ET were 
studied, using the immunobead binding assay, to determine 
the incidences of antibodies to sperm in male and female 
serum, semen and follicular fluid. The effects of various 
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types of antibodies to sperm in men and women on 
tion, cleavage and subsequent development of pregnancy in an 
IVF/ET program were analyzed. 
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MATERIALS AND METHODS 
Patients 
All consenting couples who underwent IVF/ET with 
retrieval of at least one oocyte between August and October 
1985 at Yale-New Haven Hospital were studied prospectively. 
This represented an unselected IVF/ET population of 40 
couples with infertility secondary to one of three etiolo¬ 
gies: tubal disease (n=25), male factor (n=4) or unexplained 
( n = 1 1 ) . The etiology and type (primary vs. secondary) of 
infertility, previous postcoital test (PCT) results, and 
patient age were obtained by chart review. In the classi¬ 
fication of inferti1ity,27 tubal infertility was defined by 
either absent tubes, bilaterally occluded tubes after tubal 
surgery or failure to conceive within 18 months after tubal 
surgery for tubal disease even with apparently patent tubes. 
Infertility due to male factor was defined as infertility 
associated with abnormal semen analyses (<20 x 1C)6 cells/ml, 
<60% normal morphology or <50% good progressive motility) on 
at least two occasions separated by more than three months. 
Unexplained infertility was defined as infertility for which 
no cause was found despite a complete investigation, 
including semen analysis, PCT, endometrial biopsy for 
histologic dating, hysterosalpingogram and laparoscopy. 
Informed consent was obtained from all couples prior to 
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collection of samples, and each participating couple was 
given an information sheet describing the study , There were 
three couples with tubal infertility who underwent IVF/ET 
during the interval who declined to participate. The 
protocol used was reviewed and approved by the Yale Univer¬ 
sity Human Investigations Committee (Protocol #3638). 
Collection of Samples 
Male and female serum, follicular fluid and semen were 
obtained from each couple for antisperm antibody testing. 
All samples were collected on the day of laparoscopic 
aspiration of oocytes for all but two couples studied. In 
one case, a semen sample was obtained two weeks after 
laparoscopy because all semen provided on the day of 
laparoscopy had been used for oocyte insemination. In the 
other case, the couple provided serum and semen several 
months after laparoscopy because samples were again not 
available from the time of laparoscopy. 
Blood was obtained from male and female patients by 
venipuncture and was left to clot at room temperature for 
15-30 minutes. Clotted blood was centrifuged at 800g for 8 
minutes and serum was removed for testing. Similarly 
collected female serum, which was heat-inactivated, was- used 
in various media for IVF/ET as described below. 
Follicular fluid was obtained during laparoscopic 
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aspiration of oocytes for IVF/ET at Yale-New Haven Hospital 
according to the procedures previously described by Laufer 
et al.28 Follicular fluid from a single aspirating suction 
trap, which in the vast majority of cases contained a single 
oocyte, was tested for each patient. When blood-tinged 
follicular fluid was obtained, warm heparinized medium 
devoid of serum was added to the trap and the dilutional 
factor was calculated. The particular oocyte(s) retrieved 
from the trap were noted for future evaluation of fertili¬ 
zation and cleavage parameters. After oocyte removal, the 
follicular fluid was centrifuged at 800g for 8 minutes and 
the supernatant was removed for testing. 
Semen samples tested were those used to inseminate 
oocytes for IVF/ET except in the two cases described above. 
Semen was collected by patients at the hospital after 
several days of abstinence, as per IVF/ET protocol,27 and 
was brought to the laboratory immediately after collection. 
Semen was allowed to liquify at room temperature, and an 
aliquot was removed for antibody testing after semen 
analyses were performed using a Makler counting chamber as 
previously described.29 
Testing on all fluids was begun 1-2 hours after 
collection of semen. Testing of serum and follicular fluid 
for each couple was performed using sperm obtained from that 
couple except in cases where a man's semen was positive for 
antibodies. In those cases, donor sperm was used. Any 
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serum and follicular fluid not used immediately for testing 
was stored at -70° C. 
Sera known to be positive for antisperm antibodies of 
all three isotypes by immunobead binding were kindly 
provided by Richard Bronson, M . D „ , Division of Human 
Reproduction, North Shore University Hospital, Manhasset, 
New York, and were stored in aliquots at -70° C for use as 
positive controls. Sera obtained from fertile volunteers, 
which were negative for antisperm antibodies by immunobead 
binding, were stored in aliquots at -70° C for use as 
negative controls. 
Donor semen was obtained from fertile donors partici¬ 
pating in the donor artificial insemination program. This 
semen and its sperm were found to be negative for antibodies 
to sperm by immunobead binding. Subsequently, these sperm 
were used in testing positive and negative control sera. In 
addition, in couples with semen that was positive for 
antibodies to sperm, these donor sperm were used to test for 
antisperm antibodies in the sera and follicular fluid. 
Immunobead Binding Assays 
Testing for antisperm antibodies in male and female 
serum, semen and follicular fluid was performed by immuno¬ 
bead binding assay according to the methods described by 
Bronson et al.30,31 This assay is done using immunobeads, 
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polyacrylamide spheres of 5-10 /Un diameter with covalently 
bound rabbit antibodies to the constant domain of human IgA 
(<*-chain specific), IgG (y-chain specific) or IgM (/(-chain 
specific; Bio-Rad Laboratories, Richmond, CA ; Anti-IgA, cat. 
no 170-5114; Anti-IgG, cat. no 170-5100; Anti-IgM, cat. no. 
170-5120). Lyophilized anti-IgA, anti-IgG, or anti-IgM 
immunobeads were washed once by centrifugation (800g, 8 
minutes) with Dulbecco' s phosphate buffered saline (PBS; 
Gibco Laboratories, Grand Island, NY) and were resuspended 
at 5mg/ml in PBS containing bovine serum albumin (BSA, 
fraction V; Calbiochem, La Jolla, CA) 10 mg/ml which had 
been passed through a 0.22/(m sterile filter. 
Fresh immunobead suspensions of all three isotypes, 
enough for several days of testing, were prepared in this 
manner every 3-4 days, and stored refrigerated at 4o C. 
Each fresh immunobead suspension was tested with positive 
and negative controls. Lyophilized beads could be stored as 
received from Bio-Rad refrigerated at 4o C for several 
months . 
Semen Immunobead Binding Assay 
Semen was kept at room temperature for one hour after 
ejaculation to allow unbound antisperm antibodies in the 
seminal fluid, if present, to bind to spermatozoa prior to 
testing. After adequate sperm number and motility (_>1 x 1C)6 
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motile sperm) for testing were assured by semen analysis, 
sperm were washed once by centrifugation (800g, 8 minutes) 
in PBS containing BSA 5mg/ml (BSA/PBS), resuspended, and 
washed in BSA/PBS three times using a Beckman Microfuge B 
(Beckman Instruments, Palo Alto, CA; 6 seconds per spin). 
Following the third wash, the sperm pellet was resuspended 
in BSA/PBS to 10-20 x 106 sperm/ml. BSA/PBS was remade 
every 2 days and was stored refrigerated at 4° C. 
Five Ml of this sperm suspension were added to 50 /A 1 
of well-mixed immunobead suspension, and a drop of the 
mixture was placed on a glass slide and covered with a 
coverslip. The preparation was kept at room temperature for 
10 minutes, allowing immunobead binding to occur. The 
reaction was observed and counted using phase-contrast 
microscopy at x20Q. 
Two counts of 100 motile sperm for immunobead binding 
were made on each preparation. Sperm cells without bound 
antisperm antibodies progressed through the immunobead 
suspension without binding any of the beads. Sperm cells 
with bound antisperm antibodies became bound to one or more 
beads, upon sperm-bead contact, at the region of the sperm 
surface where antibody was bound. Immunobead binding was 
designated as directed to the head, tail or tail tip of the 
sperm, indicating the presence of bound antisperm antibodies 
to that region of the spermatozoan . 
Figure 1 represents the positive immunobead binding 
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reaction d iagramatica11y. Photographs of sperm cells with 
positive and negative immunobead binding are shown in 
figures 2-4. 
Nonmotile sperm were not counted, both because they 
lacked ample opportunity to contact and bind beads, and 
because their tendency to be "stuck” nonspecif ically to 
beads was difficult to distinguish from specific binding in 
the absence of motility. Sperm-bead contact was maximized 
by gentle tapping on the coverslip to prevent sticking and 
to redistribute beads. 
The region of sperm surface to which antibody was 
directed and the percent of motile sperm cells bound was 
determined for each of three isotypes of immunoglobulin 
( I g A , I gG , IgM) . A specimen was deemed positive if _>20% of 
the motile sperm were bound to one or more bead for one or 
more of the immunoglobulin isotypes tested, as previously 
described by Clarke.18 
All specimens found to be positive were tested for the 
specificity of bead binding for each positive isotype, using 
an inhibition method described by Clarke.18 Immunobead 
binding sites were blocked by adding a drop of human IgA 
(colostral) to the anti-IgA bead suspension, IgG (poly¬ 
clonal) to anti-IgG beads, or IgM (polyclonal) to anti-IgM 
beads and leaving it at room temperature for at least 1 
minute prior to mixing with the antibody-bound sperm 
(Calbiochem, La Jolla, CA; IgA, cat no.401698, IgG, cat no 
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401105, IgM, cat no 401107, respectively). The positive 
sperm were then added to these beads and counted for binding 
as described above. 
Serum and Follicular Fluid Immunobead Binding Assay 
Each couple's male and female serum and follicular 
fluid were tested for antibody binding using the husband's 
sperm, if his sperm were negative for immunobead binding. 
In cases where a husband's sperm were positive for immuno¬ 
bead binding, antibody-negative donor sperm were used. 
Spermatozoa were selected for motility using a swim-up 
method32 i n which antibody-negative semen (containing _> 2 x 
106 motile sperm) was overlaid with BSA/PBS in a test tube 
and incubated for one hour at 37° C. Motile spermatozoa, 
which migrate to the top of the test tube, were collected, 
and 0.5-1.0 x 1C)6 of these were added to 0.4 ml of serum or 
follicular fluid, or the equivalent volume of follicular 
fluid if diluted with heparin. PBS was added for a total 
volume of 1.6 ml, making the serum or follicular fluid 
dilution 1:4, and the preparation was incubated for one hour 
at 3 7o C. The spermatozoa were than washed and tested for 
surface-bound antibody by immunobead binding as described 
above for semen. 
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In Vitro Ferti1ization/Embryo Transfer (IVF/ET) 
All patients underwent IVF/ET procedures at Yale-New 
Haven Hospital as previously described. Induction of 
follicular growth was achieved using either human menopausal 
gonadotrophins (hMG, Pergonal; Serono Laboratories Inc., 
Randolph, MA), hMG + clomiphene citrate (Clomid, Merrell- 
Dow; Cincinatti, OH), or purified follicular stimulating 
hormone (FSH; Metrodin; Serono Laboratories Inc.). Follic¬ 
ular development was monitored by ovarian ultrasonography 
and daily serum estradiol measurements beginning on day 8 of 
the cycle. Human chorionic gonadotrophin (hCG, Pregnyl; 
Organon, West Orange, NJ) was administered to stimulate ovum 
maturation once two follicles >.1.6 cm in diameter were seen 
on ultrasound and serum estradiol was >400 pg/ml.32 
Oocytes were aspirated by laparoscopy and graded for 
maturity, based on the degree of cumulus mucification and 
corona cell dispersion, as immature, intermediate and mature 
as previously described.28 Intermediate and mature oocytes 
were uniformly inseminated, 6-8 hours after retrieval, with 
0.5 x 10^ spermatozoa washed twice with insemination medium 
and obtained by swim-up. Modified Ham's F-10 medium 
enriched with 10% of the individual woman's heat-inactivated 
serum was used as insemination medium. Ova were moved from 
insemination medium to growth medium, consisting of modified 
Ham's F-10 with 20% of the woman's serum, 16 to 18 hours 
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after insemination. The oocytes were examined for the 
formation of pronuclei at this time. Embryos of two or more 
cells were transferred to the uterus 38-40 hours after 
insemination, in transfer medium containing modified Ham's 
F-10 with 90% of the woman's serum. The luteal phase was 
supported with daily intramuscular progesterone. Women were 
followed for pregnancy with radioimmunoassays for - hCG 
and serum estradiol as previously described.28 
Fertilization rate was calculated including only 
oocytes graded as intermediate and mature which were 
inseminated uniformly as described above. Fertilization was 
defined by the presence of two or more pronuclei. Cleavage 
rate was calculated as the proportion of fertilized oocytes 
which cleaved. Cleavage was defined as zygote division. 
Statistical Analysis 
Appropriate statistical analysis was performed using 
Student T-tests, Chi-square analysis, and Fischer's exact 
test.33 Data are expressed as mean+SEM. 
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RESULTS 
Negative controls tested were found to have occasional 
binding (0-10%) of the motile spermatozoa, particularly to 
tail tip. Consequently, a cutoff of >_20% immunobead binding 
was used to define positives in table 1 and all subsequent 
data reported. 
The specificity of antibody binding to sperm in all 
positive specimens was affirmed by an inhibition test. In 
this test, a specific positive reaction to a particular 
isotype of immunoglobulin was inhibited when an adequate 
concentration of that immunoglobulin to block the immunobead 
binding sites was first mixed with beads. Thus, in this 
study, immunobead binding was inhibited for all samples 
which were positive for IgA class antibodies to sperm after 
free IgA had been mixed with the anti-IgA immunobeads. 
Similarly, positive reactions were inhibited for samples 
positive for IgG class antibodies to sperm after addition of 
free IgG to anti-IgG immunobead beads and for samples 
positive for IgM class antibodies to sperm after addition of 
free IgM to anti-IgM immunobeads. 
Incidence of Antibodies to Sperm 
A complete listing by couple of the results of 
immunobead binding assays and of IVF/ET outcome for the 40 
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couples studied is shown in table 1. For each couple 
studied, immunobead binding results are given for three 
regions of antibody binding to sperm--head, tail tip and 
tail, in each of the 4 fluids tested. IVF/ET results shown 
include fertilization rates (listed in increasing order), 
cleavage rates and pregnancy outcome. The etiology of 
infertility for each couple is also shown. 
The immunobead binding data shown in table 1 is 
summarized in table 2. The frequency of immunobead binding 
by fluid and region of antibody binding on sperm may be 
seen. Thus, in an unselected population of IVF/ET patients, 
antibody binding to sperm head was present in 15% of female 
sera and 13% of follicular fluid samples. Antibodies to 
sperm head were present in the follicular fluid of 5 of the 
6 women with these antibodies in their serum (83%, table 1, 
couples# 1,3,11,13,33). All women with antibodies to sperm 
head in follicular fluid also had antibodies to sperm head 
in serum. In each of these 5 cases, the follicular fluid 
was positive only for immunoglobulin isotypes which were 
also positive in female serum (table 3). 
Antibody binding to sperm head was present in 8% of 
semen samples and 8% of male serum tested (table 2). As 
seen in table 1, there was overlap between these two groups. 
Two men (table 1, couples# 33,34) had antibodies to sperm 
head in both semen and serum. There was one man with 
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antibodies to sperm head in semen alone (couple# 2) and one 
man with antibodies to sperm head in his serum alone 
(couple# 14). The mean sperm concentration and percent 
motility by semen analysis in men with antibodies to sperm 
head in either semen, serum or both (n=4) did not differ 
significantly from those in men without antibodies to sperm 
head (n=36; 105 + 23 x 10^ sperm/ml, 60 + 8% and 113+^13 x 10^ 
sperm/ml, 64+2%, respectively). 
Antibody binding to sperm tail tip, the region of sperm 
most frequently bound, was present in 30% of the female 
sera, 25% of the follicular fluid samples, 10% of semen 
samples, and 30% of male sera tested. 
Antibody binding to sperm tailpiece (tail), the region 
of sperm least frequently bound, was present in 5% of female 
sera, 3% of follicular fluid samples, 3% of semen samples 
and 5% of male sera tested. All specimens with- binding to 
sperm tailpiece also had binding to sperm head (table 1, 
couples# 1,11, 33,34). 
The distribution of binding by immunoglobulin isotype 
(IgA,IgG,IgM) for each region of antibody binding on sperm 
in each fluid tested is shown in table 3. Analysis of 
individual antibody isotypes was not as useful as the use of 
all three isotypes combined in predicting fertilization in 
any of the fluids tested. Thus, the isotypes have been 
grouped together for all analyses described here. 
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Antibodies to Sperm Head and Subsequent Fertilization 
Analysis of the effect of antisperm antibodies on 
fertilization will be reported for each region of antibody 
binding to sperm in each fluid tested, following the 
organization of table 2. As shown in table 2, fifteen 
percent (6/40) of women tested had antibodies to sperm head 
in their serum. Among these women, the oocyte ferilization 
rate of uniformly inseminated mature oocytes was signifi¬ 
cantly reduced. As shown in figure 5, 9 of the 27 oocytes 
(33%) inseminated were fertilized, as compared with 118 of 
167 oocytes (71%) of women without antibodies to sperm head 
in their serum (p<0.001). Of the women in whom no oocytes 
fertilized, 60% (3/5; table 1, couples# 1,2,3) had antibod¬ 
ies to sperm head in their serum, while only 9% (3/35; 
couples# 11,13,33; p<0.05) of those who had at least one 
oocyte which fertilized had antibodies to sperm head. Serum 
antibodies to sperm head were found in 5 of the 13 women 
whose fertilization rate was <60% (table 1, couples# 
1,2,3,11,13), and in 1 of the 27 women whose fertilization 
rate was >60% (coupl e# 33; p<0.05). For all couple s with 
antibodies to sperm head in female serum (n = 6 ) , the mean 
fertilization rate was 34-j-17% compared to 74 + 6 % in those 
without antibodies to sperm head (n=34 ; p=0.01). 
As shown in table 2, 13% of women tested had antibodies 
to sperm head in follicular fluid. Fertilization rates of 
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uniformly inseminated mature oocytes were calculated for the 
particular oocyte(s) retrieved from follicular fluid tested. 
The presence of antibodies to sperm head in follicular fluid 
was associated with decreased fertilization. As seen in 
figure 5, among women with antibodies to sperm head in 
follicular fluid, 29% (2/7) of oocytes were fertilized as 
compared with 66% (27/41) of oocytes in women without. 
Although this is not a statistically significant difference 
because of the small numbers involved, it is highly sugges¬ 
tive of a trend. 
As summarized in table 2, the incidence of antibodies 
to sperm head was 8% in semen and 8% in male serum. Neither 
semen nor serum antibodies to sperm head significantly 
affected the oocyte fertilization rate (figure 5). 
Antibodies to Sperm Tail Tip and Tail and Subsequent 
Fertilization 
Antibody binding to sperm tail tip occurred more 
frequently than binding to either sperm head or tail in each 
fluid tested (table 2). It occurred in 30% of female sera, 
25% of follicular fluid samples, 10% of semen and 30% of 
male sera tested. Despite its frequent occurrence, antibody 
binding to sperm tail tip did not reduce the oocyte fertili¬ 
zation rate significantly in any of the fluids tested 
(figure 6). 
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Antibody binding to sperm tailpiece was rare in all 
fluids (table 2). The number of patients with antibodies to 
tailpiece was too few to examine the effect of tailpiece 
antibodies on fertilization. 
Subsequent analyses examine the clinical significance 
of antibodies to sperm head, particularly in female serum, 
for two reasons. First, antibodies to sperm head in female 
serum and follicular fluid have apparent importance to 
fertilization. Second, antibodies to sperm tail and tail 
tip lacked clinical relevance to fertilization in this 
study . 
Antibodies to Sperm Head in Female Serum and Cleavage 
Among women with serum antibodies to sperm head, 
oocytes that did fertilize were capable of cleavage. 
However, the zygote cleavage rate was reduced in the 
presence of serum antibodies to sperm head (figure 7). 
Among women with serum antibodies to sperm head, 67% of 
zygotes (6/9) were cleaved, as compared with 91% of zygotes 
in women without serum antibodies to sperm head (107/117; 
p=0.051). Of the 6 cleaved embryos in the former group, 4 
were 3-4 cell embryos and 2 were >4 cell embryos at the time 
of transfer to the uterus. 
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Antibodies to Sperm Head in Female Serum and Pregnancy by 
IVF/ET 
Among women with serum antibodies to sperm head, 
oocytes that fertilized and cleaved were capable of implan¬ 
tation leading to a normal pregnancy. There was no signi¬ 
ficant difference in the pregnancy rate of women with and 
without serum antibodies to sperm head in this sampling 
(figure 7). One of the 6 women with serum antibodies to 
sperm head (17%) conceived and has continued with a normal 
pregnancy confirmed by ultrasound. Seven of the 34 women 
without serum antibodies to sperm head (21%) became preg¬ 
nant; 3 have ongoing pregnancies documented by ultrasound; 2 
had spontaneous abortions after their pregnancies were 
documented by ultrasound, and 2 had chemical pregnancies. 
Antibodies to Sperm Head and Etiology of Infertility 
Sixty-three percent of couples tested had tubal 
infertility, 10% were infertile secondary to a male factor, 
and 28% had unexplained infertility (table 1). The inci¬ 
dence of antibodies to sperm head in unexplained infertility 
and tubal infertility are shown in figure 8. Comparing 
couples with unexplained (n=ll) vs. tubal (n=25) infertil¬ 
ity, 46% and 4% respectively had antibodies to sperm head in 
female serum (p=0.006), 36% and 4% had antibodies to sperm 
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head in follicular fluid (p=0.023), 27% and 0% had antibod¬ 
ies to sperm head in semen (p=0.023), and 18% and 4% had 
antibodies to sperm head in male serum (p=0.022). Antibod¬ 
ies to sperm head were present in one or more fluids tested 
in 55% of the patients with unexplained infertility compared 
to 8% of patients with tubal infertility (p=0„005). Of the 
-6 women with antibodies to sperm head in their serum, 83% 
(5/6) were undergoing IVF for unexplained infertility 
compared to 17% (1/6; p=0.08; figure 9) who had tubal 
infertility. 
Serum Antibodies to Sperm Head and Primary vs. Secondary 
Infertility 
Of the 6 couples with antibodies to sperm head in 
female serum, infertility was primary for 4 and secondary 
for 2. In these couples, the mean sperm concentration was 
almost twice as high for those couples with secondary 
infertility as for couples with primary infertility. 
Specifically, the mean sperm concentration and percent 
motility of couples with secondary infertility and antibod¬ 
ies to sperm head in female serum were 102^11 x 106 sperm/ml 
with 6670 + 9 motility, compared to 65+^30 x 106 sperm/ml with 
57 7o+_6 motility for couples with with primary infertility 
antibodies to sperm head in female serum. This difference 
is not statistically significant because of the small 
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numbers involved, but suggests a trend. Among couples with 
antibodies to sperm head in female serum, a higher number of 
motile sperm was associated with previous fertility. 
Women with serum antibodies to sperm head were similar 
in age to women without (mean ages 35+^2 and 34 + 1, 
respectively). 
Antibodies to Sperm Head in Female Serum and Semen and PCTs 
Results of previous PCTs were available in the medical 
charts of 23 of 40 of the couples tested. Because of 
inconsistencies in the methods of documenting PCT results, a 
controlled comparison cannot be made. However, available 
results for couples with antibodies to sperm head in female 
serum or semen are reported here. Of the 6 women with 
antibodies to sperm head in serum, 4 (67%) had had only 
abnormal PCTs in the past, 1 had had a good PCT (17%), and 1 
had no PCT documented in the chart. Two of the 3 men with 
antibodies to sperm head in semen had PCTs documented in the 
chart: one had had abnormal PCTs in the past; the other 
had had a PCT considered to be within normal limits. 
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DISCUSSION 
The Immunology of Reproduction 
The growth of the immunology of conception as a field 
of scientific and clinical interest should not be surprising 
in view of our knowledge of the importance of the immunology 
of pregnancy. In fact, more than 40 years before 
Landsteiner and Weiner (1940)34 and Levine et al (1941)35 
delineated isoimmunization as the cause of hemolytic disease 
in the fetus and newborn, Landsteiner (1899)36 had demon¬ 
strated the antigenicity of sperm. In 1932, Baskin37 
reported the induction of transient sterility in 20 women as 
a result of immunization with human spermatozoa for contra¬ 
ception. Subsequent studies38,39,40,41,42,43 have reported 
the antifertility effects of experimentally-induced antibod¬ 
ies to sperm in many animal species. In recent years, in 
vitro studies using animal mode1s^^^5,46,47,48,49,50,5 1 
which demonstrate impairment of the egg-sperm interaction in 
the presence of antisperm antibodies have provided further 
evidence that antibodies against sperm may compromise human 
reproduction. 
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Pathogenesis of Immunity to Sperm 
The pathogenesis of immunity to sperm still remains 
largely a mystery. Mature sperm cells first appear in the 
male at puberty, long after the development of immunocompe- 
tence and tolerance to "self" antigens. Since spermatozoa 
express antigens which are foreign to the immune system, 
their immunogenicity is not surprising. 
Sperm are normally sequestered from the immune system 
by a blood-testis barrier formed by the tight junctions of 
Sertoli cells in the seminiferous tubules52 and epithelial 
cell barriers elsewhere in the male reproductive tract.53 
Disruption of the blood-testis barrier by vasectomy has been 
associated in many men with the formation of antibodies to 
sperm, presumably due to sperm antigen leakage.53,54 Other 
processes,^3 like trauma, inflammation or irradiation of the 
testes, or obstruction of the tubules or ducts of the male 
reproductive tract, might similarly stimulate antisperm 
antibody formation. This might occur either by increasing 
the permeability of the male reproductive tract to immuno¬ 
competent cells or by allowing the passage of sperm antigens 
through the blood-testis barrier. In fact, these associa¬ 
tions have led to the speculation that the formation of 
a u t o a n t i b od i e s to sperm could be a part of a reproductive 
strategy in the male which prevents genetically abnormal 
spermatozoa from participation in ferti1ization . 55 
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However, large gaps exist in our understanding of the 
pathogenesis of immunologic infertility in the male. Some 
men who have undergone vasectomy do not develop autoantibod¬ 
ies to sperm,54 while many infertile men are found to have 
antisperm antibodies, but have no known history to explain 
sperm extravasation across the blood-testis barrier.43 The 
relevance of the quantity, rate and type of antigen expo¬ 
sure, and variation in the immune response among individuals 
is undetermined at present. 
The mechanisms of isoimmunization to sperm in the 
female are even less clear than in the male. Through sexual 
activity, the female reproductive tract is repeatedly 
innoculated with immuno1ogica 11y-foreign sperm cells, and 
yet only a minority of women develop immunity to sperm. 
Several factors are felt to inhibit an immune response to 
sperm in most women. First, most sperm cells remaining in 
the female reproductive tract after coitus are normally 
phagocytosed by macrophages and neutrophils before an immune 
response develops.8 Second, one or more immunosuppressive 
factors in seminal fluid are believed to prevent sensitiza¬ 
tion to sperm.56 
Despite these factors, an immune response to sperm 
develops in some women. After sexual intercourse, antibod¬ 
ies to sperm may develop locally or sperm may reach the 
peritoneal cavity where immunologic stimulation may occur.8 
Factors, such as infection, in the female reproductive tract 
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may either act as adjuvants which stimulate local immune 
responsiveness, alter the effectiveness of immunosuppressive 
factors in seminal plasma or lead to the formation of 
antibodies that cross-react with sperm.8,57 Alternately, 
sperm may innoculate the gastrointestinal tract. Gastroin¬ 
testinal exposure to sperm after oral or anal intercourse 
has been associated with the formation of antisperm antibod¬ 
ies in studies of homosexual men.58,59 
The need to identify specific antigens on sperm 
involved in immunologic infertility is apparent. Several 
labs 60,61,62 have produced monoclonal antibodies to human 
sperm components in efforts to delineate specific sperm 
antigens. One monoclonal antibody, which cross reacts with 
human sperm and testes, monkey sperm and mouse sperm, has 
been shown to block penetration by human sperm of zona-free 
hamster ova.60 Characterization of the antigens involved in 
immunologic infertility would permit highly specific 
identification of affected couples and definition of the 
sites of reproductive impairment and leading to more 
effective therapy. In addition, identification of a 
specific antigen which impairs fertilization in a well- 
defined and circumscribed manner would make the development 
of immunocontraception possib1e.^,63 
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Assays of Antisperm Antibodies 
A number of assays have been used in attempts to detect 
antibodies to sperm (table 4).13,64 The methods which rely 
on sperm cell agglutination [tray-slide agglutination test 
( T S A T ) , ^ gel agglutination test (GAT) ,65 tray agglutination 
test (TAT)66] lack specificity and reliability because sperm 
cells agglutinate in the absence of specific antibody under 
a variety of conditions.7,13,64 These include the presence 
of bacteria, fungi or amorphous materials in semen, and sex 
steroids or nonimmunoglobulin proteins in serum. M e n g e 8 
compared the mean incidences of agglutination determined by 
investigators using various agglutination methods in more 
than ten reports and found that the mean incidence of sperm 
agglutination in the sera of pregnant controls was 35-38%, 
higher than the 15-23% incidence found in the women with 
unexplained infertility. Perplexing variation was found, 
particularly with the TSAT, where mean incidences of serum 
antisperm antibodies in seven studies ranged from 14-67% of 
women with unexplained infertility. Agglutination methods, 
in addition to their nonspecificity and unreliability, do 
not define the isotype(s) of immunoglobulin involved, and 
none but the TAT indicate the region of sperm to which 
antibody is bound.67 
The sperm immobilization test (SIT),64,68 which detects 
complement-dependent immobilization and cytotoxicity, is 
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highly specific and reproducible. However, Bronson^l has 
demonstrated its insensitivity to IgA isotypes which do not 
fix complement, and to antibodies bound to sperm head which 
do not cause sperm immobilization. Some of these undetected 
antibodies have been shown to interfere with the sperm-egg 
interaction.^ The SIT is a useful, reliable clinical test 
for antisperm antibody activity, but its utility is limited 
by its insensitivity to certain antisperm antibodies and its 
inability to identify the region of antibody binding to 
sperm. 
Immunofluoresence techniques^, 70 have been associated 
with a high incidence of false positives and poor correla¬ 
tion with fertility status because methanol fixation exposes 
internal sperm antigens. Antibodies to these antigens are 
felt to play no role in infertility.^ This test is not 
suitable for routine clinical screening, but may be a 
valuable research tool because it identifies the region of 
antibody binding to sperm.^3 
Enzyme-linked Immunosorbent Assays (ELISA),71,72,73,74 
use an enzyme-1 abe1ed antiglobulin which binds to human 
immunoglobulins on the sperm surface. The presence of the 
enzyme may be detected and measured colorimetrically upon 
addition of the enzyme substrate. Fixation of either whole 
sperm71,73,74 or sperm membrane extracts72,73 are required 
as antigenic targets. However, sperm antigens appear to be 
altered by the process of sperm fixation involved, contri- 
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buting to a high false positive and negative rate.74,75 
Assays using whole sperm have not shown clinical correlation 
with infertility.75 Until clinically significant antigens 
are identified and isolated for use as antigen targets, this 
test has limited clinical utility. 
In the recently described "panning9* assay, 76 antibody 
bound sperm sticks to wells coated with antiglobulin 
molecules. The assay, which is qualitative and does not 
identify the region of antibody binding to sperm, has been 
shown to detect those antibodies detected by agglutination 
but not immunofluoresence assays.75 Its sensitivity, 
specificity and clinical value are unknown. 
Although cervical mucus appears to be an important site 
of immunologic infertility, it is often not tested for 
antibodies to sperm because of the difficulties in collect¬ 
ing and processing it.7 Antibodies to sperm in cervical 
mucus and semen may be detected by simple visual observation 
of the "shaking phenomenon" using the Sperm-Cervical Mucus 
Contact Test (SCMCT).77 When antibody-bound sperm contact 
cervical mucus on a slide, the characteristic shaking 
reaction seen is felt to result from cross-linking of motile 
antibody-coated sperm to the cervical mucus gel via the Fc 
portion of the antibody molecule.78 "Crossover" testing 
using donor sperm and cervical mucus discriminates between 
antibodies in the male and female. Although it is a 
qualitative test with unknown specificity and sensitivity, 
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it is a simple, valuable method to detect antisperm antibod¬ 
ies in cervical mucus.79 
In radiolabeled antiglobulin assays,^ radiolabeled 
antibodies detect human immunoglobulins bound to sperm. 
These techniques are highly sensitive and specific.13 The 
technique, best used on living sperm, can determine isotype 
of immunoglobulin in semen or serum and supply quantitative 
results. However, since the regional specificity of binding 
to sperm cannot be determined, the assay provides no 
information about the antigens involved in the immune 
response detected. 
The mixed agglutination reaction (MAR)80 is based on 
the Coombs mixed agglutination reaction.81 Rh-positive human 
red blood cells sensitized with a human IgG anti-Rh antibody 
is mixed with semen and rabbit anti-human IgG antiserum. A 
mixed agglutinate of sperm and red blood cells occurs in the 
presence of antibody-bound sperm. The test is highly 
specific and useful to detect antibodies bound to sperm in 
semen,82 however, it has only been used reliably to detect 
IgG isotype.18 In addition, the region of antibody binding 
to sperm and extent of binding are difficult to determine.13 
The immunobead binding assay provides a highly specific 
and reproducible method of detecting antibody bound to the 
sperm surface.17 It determines the isotype of immunoglob¬ 
ulin bound, the percent of sperm which are antibody bound 
and most importantly, the region of sperm to which specific 

34 
antibody is bound. It can measure antibodies in males and 
females, in both sera and local reproductive secretions and 
fluids. The sensitivity of the assay has not been deter¬ 
mined, 13 because there is no assay accepted for its clini¬ 
cal 1 y - r e 1 e v a n t sensitivity for use as a standard for 
comparision. However, its findings are proving to correlate 
highly with clinical infertility status. In various studies 
using immunobead binding, Bronson has found significant 
correlation between antibody binding and decreased concep¬ 
tion rates,^ decreased in vitro binding to the zona 
pellucida by human spermatozoa,19 and abnormal PCTs.^O 
Sites of Immunologic Infertility 
The various sites where antibodies to sperm may 
interfere with reproductive success are shown in table 5. 
Antisperm antibodies may impair reproduction at the level of 
spermatogenesis, sperm transport, sperm survival, gamete 
interaction, and embryo surviva1.8,13,14,43,83 Jn addition, 
several immunologic responses other than humoral immunity to 
sperm have been suspected of immunologic impairment of 
ferti1ity.7,43 Cellular immunity to sperm84,85 and humoral 
immunity to the zona pellucida of the ova86,87,88,89,90 have 
recently received attention for their potential role in 
£ 
infertility. Studies of these immunologic responses in 
infertility have taken a back seat to the study of antisperm 
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antibodies, because of some of the technical difficulties of 
conducting studies in these areas, and because of the weight 
of evidence implicating antisperm antibodies in infertil¬ 
ity. 7 The current study examines the effect of antisperm 
antibodies on gamete interaction. 
A number of studies^, 30,91,92 have used zona- free 
hamster ova93 to assess fertilization by human spermatozoa 
with bound antisperm antibodies. All but one of these 
studies^O indicates that antisperm antibodies inhibit sperm 
binding to the zona-free hamster ova. Bronson^ showed that 
normal human sperm with antibodies bound to the sperm head 
failed to bind to salt-stored human zona-pe11ucidae . 
Kamada23 demonstrated that zona penetration, in addition to 
zona binding, is inhibited by antibodies bound to sperm. 
The implication of these studies is that antisperm antibod¬ 
ies interfere with the sperm-egg interaction, either the 
acrosome reaction, zona binding and/or penetration, or 
sperm-egg fusion. 
None of these studies provides a look at both sperm- 
zona interaction and sperm-egg fusion in the same system. 
Clarke26 studied men with sperm antibodies undergoing IVF/ET 
and found that in the presence of high levels of IgA and IgG 
class i soantibodies to sperm, fertilization was reduced. 
However, he did not make distinctions on the basis of region 
of antibody binding to sperm. In this study, Yale-New Haven 
Hospital IVF/ET data from both women and men with antibodies 
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to sperm was analysed to further examine the effect of 
antibodies to sperm in female and male sera and local 
reproductive fluids on the total sperm-egg interaction. 
Immunobead binding to at least 20% of sperm was used in 
the current study as the cutoff for positive antibody 
binding, based on the low levels of nonspecific binding 
(<10 %) found in fertile negative controls. The cutoff 
correlated well with clinical findings by identifying a 
group of positives with a significantly decreased fertili¬ 
zation rate in IVF and is consistent with the 20% cutoff 
used by Clarke. 18 Bronson's groupll*20 has used a cutoff of 
50%, based on his findings of a significantly reduced 
spontaneous conception rate and impaired cervical mucus 
penetration in those with >50% binding. The 50% cutoff was 
not used in the current study because it would exclude a 
substantial number of couples with antibodies to sperm who 
had no fertilization of oocytes. 
Clarke recently reported the finding that IgG and IgA 
are the two major immunoglobulin classes of antibodies to 
sperm in female and male serum, 94 ancj an follicular fluid.95 
This was not confirmed in the current study. No statisti¬ 
cally significant relationship was found between isotype of 
immunoglobulin and either location in particular biologic 
fluids or clinical significance in this study. Further 
investigation is necessary to define the role, if any, of 
immunoglobulin class in infertility. 
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Antibody-negative donor sperm were used as an antigen 
source while testing for antisperm antibodies in control and 
other sera where necessary. This widespread practice has 
been adopted based on reports that antibodies to sperm are 
tissue-specific rather than human leukocyte antigen (HLA)- 
specific.^ Because HLA or ABO group antigens are not 
expressed on human sperm,96 the antibody findings for a 
given fluid (serum, follicular fluid, seminal plasma) are 
the same when sperm from different individuals is used as 
the antigenic target. As expected, this was confirmed in 
the current study by the uniform antibody binding pattern 
detected in positive control serum when sperm from several 
donors were used as the antigen source. In addition, 
analysis of HLA antigens in couples with unexplained 
infertility in two studies97,98 has revealed no association 
between infertility and intracouple HLA compatabi1ity. 
Antibodies to Sperm Head and Subsequent Fertilization 
In women with serum antibodies to sperm head, the ova 
and/or sperm were directly exposed to these antibodies from 
several sources in vitro, in addition to any possible in 
vivo exposures. These include exposure to antisperm 
antibodies from female serum in insemination, growth and 
transfer media, from follicular fluid in the aspirating trap 
and from any follicular fluid antibodies remaining in the 
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cumulus mass at the time of insemination. Thus, the finding 
in this study that IVF/ET fertilization rates are reduced in 
women with antibody to sperm head in serum and follicular 
fluid indicates that fertilization is impaired in the 
presence of antibodies to sperm head. This is consistent 
with previous findings which suggested that antisperm 
antibodies interfere with the sperm-egg interaction23,91,92 
and that women with immune infertility have impaired 
fertilization.99 
The presence of antibodies to sperm in the follicular 
fluid showed a clear relationship to antibody findings in 
serum. All women with antibodies to sperm head in follic¬ 
ular fluid also had antibodies in serum, and each isotype 
that was positive in follicular fluid was also positive in 
serum. This confirms the findings of Ackerman, et al.21 in 
the one case for which the serum was positive and the 
follicular fluid was not, and the few cases in which one 
isotype in serum was not found in follicular fluid, a 
dilutional effect appears to be the cause; these women had 
lower concentrations of antibody in serum and the concen¬ 
trations of antibody in their follicular fluid just missed 
the 20% cutoff involved. 
The antibodies in follicular fluid may be due to local 
production , ^ 1 transudation from serum^ or from vascular 
injury by the aspirating needle during aspiration of 
follicles21 resulting in collection of blood with the 
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follicular fluid. In any case, follicular fluid antibodies 
are clinically relevant in IVF/ET because the ova are 
exposed to the antibody-containing follicular fluid and 
antibodies may remain on the cumulus at the time of insemi¬ 
nation. In vivo, the ovum is similarly exposed to follic¬ 
ular fluid antibodies within the follicle, and may retain 
those antibodies in the cumulus mass. In addition, follic¬ 
ular fluid from the ruptured follicle may enter the fallo¬ 
pian tube and impair the egg-sperm interaction.^ 
Antibody binding to sperm head in semen and male serum 
did not impair fertilization in the current study. This 
lack of correlation with fertilization cannot be regarded as 
conclusive because the number of positives in this group 
were so few. Clarke26 has reported a reduced fertilization 
rate in IVF in men with >^80% isoantibodies bound to sperm 
and a normal fertilization rate in men with <80% of sperm 
bound. Further studies must be conducted to investigate the 
clinical significance of antibody binding to sperm head in 
the male. 
Antibodies to Sperm Tail Tip and Subsequent Fertilization 
Particularly significant is the finding that antibodies 
to sperm tail tip had no effect on fertilization. Thus, the 
region of antibody binding to sperm appears clinically 
relevant. This is consistent with previous studies by 
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Bronson which indicate that antibodies to sperm head inhibit 
sperm binding to the zona pellucida!9 and antibodies to 
sperm tail tip probably play no role in infertility.13 
These findings indicate that organization of antibody 
findings by region of binding is a critical step in distin¬ 
guishing between clinically significant and insignificant 
antibodies. 
Antibodies to Sperm Head and Subsequent Cleavage and 
Pregnancy 
Once fertilized, oocytes from women with serum antibod¬ 
ies to sperm head were capable of cleavage and pregnancy. 
H o wever,s i nce sperm-specific surface isoantigens have been 
detected on the egg after fertilization, antisperm antibod¬ 
ies may act directly to impair cleavage, implantation or 
embryo survival.100 In fact, in the current study, antibod¬ 
ies to sperm head in female serum were associated with a 
reduced rate of zygote cleavage. This is in contrast to a 
previous study involving 3 women with immunologic infertil¬ 
ity undergoing IVF/ET in which cleavage was not impaired.24 
Since the total number of fertilized oocytes from women with 
antibodies to sperm head in the current study was nine, 
future studies of cleavage in women with head-directed 
antisperm antibodies must be conducted on a larger scale. 
The pregnancy rates using IVF/ET in women with and 
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without serum antibodies to sperm head were not signifi¬ 
cantly different in the current study. Since the spontane¬ 
ous pregnancy rate is reduced in couples with antisperm 
antibodies,7,11 this finding suggests a therapeutic advan¬ 
tage for IVF/ET for couples with antisperm antibodies. 
Further studies must assess the pregnancy rate in IVF/ET in 
women with serum antibodies to sperm head on a larger scale. 
Antibodies to Sperm Head and Unexplained Infertility 
Populations of infertile couples undergoing IVF/ET 
include a large percentage of patients whose infertility is 
unexplained. An immune etiology has been suspected for a 
subset of these patients.2 The immunobead testing in this 
study indicates that antibodies to sperm are present in 
members of an IVF population, particularly in couples whose 
infertility is considered unexplained. 
The strong correlation between antibodies to sperm head 
and unexplained etiology is not surprising. Previous 
studies which did not identify the region of antibody 
binding to sperm have reported a high incidence of antisperm 
antibody findings in populations with unexplained infertil¬ 
ity. The added definition of region of sperm binding in the 
current study permits greater specificity in identifying 
patients affected with infertility on an immune basis. That 
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is, we can now distinguish in a clinically relevant way 
between types of positives by region of binding, in view of 
the apparent clinical insignificance of binding at some 
sperm locations and possibly in some fluids. 
Antisperm Antibodies and Primary vs. Secondary Infertility 
Among couples with antibodies to sperm head in female 
serum, the history of prior conceptions in those with higher 
numbers of motile sperm suggests several important concepts. 
First, immunologic infertility may be relative rather than 
absolute j 1 3 since conceptions in vivo occurred in this 
group. Second, factors in infertility are additive, and it 
appears to be advantageous to maximize all factors contri¬ 
buting to fertility. A higher number of motile sperm in a 
couple with antibodies to sperm head in female serum appears 
to be p r o g no s t i c a 11 y better. Third, some or all of the 
couples who had conceived in the past may not have had 
antibodies to sperm when they previously conceived. Study 
of couples with immunologic infertility who have previously 
conceived might help us identify those couples at risk for 
developing immune infertility. 
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Antisperm Antibodies and PCTs 
A PCT1 is an examination of the cervical mucus after 
sexual intercourse around the time of ovulation to assess 
the quality and number of motile sperm in the cervical 
mucus, as well as the quality of the cervical mucus itself. 
PCT results were available in only some of the patients 
studied. The criteria used in these tests and the types of 
documentation in the medical charts were nonuniform. 
However, four out of five of those women with antibodies to 
sperm head who had PCT results documented in their charts 
had abnormal PCTs. This confirms a number of previous 
studies which have correlated antisperm antibodies with 
abnormal PCTs.13,20,77,101 
The PCT is a good nonspecific way of screening for 
antisperm antibodies because immunoglobulin-bound^ sperm have 
impaired ability to penetrate cervical mucus.^ In one 
study, 13 intermediate to high levels of circulating anti¬ 
sperm antibodies were present in 23% of men and 35% of women 
in an infertile population with abnormal PCTs, despite 
normal semen analyses. 
However, an abnormal PCT may be caused by many factors, 
including occult infections like chlamydia or mycoplasma, 
poor mucus quality due to hormonal factors, poor semen 
quality or improper timing of PCT.1,2,101 in cases where an 
abnormal PCT is unexplained, in vitro sperm-mucus testing 
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should be performed.2 The SCMCT77 provides a controlled 
method of examining the semen and cervical mucus for 
antisperm antibodies and can distinguish between antibodies 
to sperm in the semen and cervical mucus using a crossover 
technique „ 
•IVF/ET as Therapy for Immunologic Infertility 
IVF/ET compares well with other currently employed 
methods of treatment for immunologic infertility, including 
condom or occlusive therapy,102 immunosuppression with 
corticosteroids^^ and intrauterine i n s e m i n a t i o n . 1 0 3 
Varying success rates have been reported for these methods 
but none have been shown to be very effective therapy for 
immunologic infertility.^ Isojima et all04 reported that 
titers of antibodies to sperm remained unchanged in a woman 
whose husband used condoms to decrease his wife's sensiti¬ 
zation to sperm by removing exposure to sperm antigens. 
Studies using corticosteroid immunosuppression have yielded 
contradictory results,^05,106 A recent double-blind, 
randomized, p 1 acebo-contro11ed clinical triall06 demon¬ 
strated no significant effect of intermittent high doses of 
prednisolone on antisperm antibody levels and semen charac¬ 
teristics . 
Various methods^ Qf in vitro manipulation of semen, 
like sperm washing,102 prior to intrauterine insemination 
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have been used for men with autoimmune infertility. Sperm 
washing techniques have failed to reduce the proportion of 
sperm which are antibody bound and may lead to loss of sperm 
function.13 Techniques which use rapid high volume dilution 
of freshly-ejaculated unbound sperml3 and freeze-thawed 
sperm membrane fragments as immunosorbent^^ have been 
reported to reduce the proportion of antibody-bound sperm 
and must be tested further. Intrauterine insemination to 
bypass antisperm antibodies in the cervical mucus of 
isoimmune women does not eliminate the problem of impaired 
fertilization due to antisperm antibodies in serum and 
within the reproductive tract in these women.103 
The promise of IVF/ET for immunologic infertility lies 
in the opportunity to employ appropriate methods to minimize 
antibody impairment of fertilization. In autoimmune men, 
in-vitro manipulations of sperm, such as rapid semen 
dilution, might be used to reduce the proportion of 
antibody-bound sperm. In women with antisperm antibodies in 
serum and follicular fluid, elimination of the antibody- 
containing female serum from all IVF/ET media would reduce 
direct exposure of the ova and sperm to antibodies in female 
serum. Washing follicular fluid from the cumulus mass might 
remove residual antibodies from the fertilization environ¬ 
ment. These and other modifications of IVF/ET methodology 
should improve fertilizing ability for couples with antibod¬ 
ies to sperm head. 
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The few reports of IVF/ET in couples with immunologic 
infertility indicate that IVF/ET may offer a chance for 
conception to couples with antibodies to sperm who cannot 
conceive otherwise. This may be accomplished using IVF/ET 
with or without the use of methodological modifications. In 
the current study, pregnancies were achieved in couples with 
male and female immunologic infertility without any modifi¬ 
cation of IVF/ET methods. Ackerman et a 121 and Yovich et 
al22,102 each reported pregnancies in women with serum 
antisperm antibodies (table 6). Both of these groups used 
IVF/ET media which contained no patient serum, substituting 
either human fetal cord or donor serum, and employed a 
procedure to wash the cumulus mass free of follicular fluid 
prior to insemination. Kamada et al23 and Clarke et al24 
eliminated patient serum from IVF/ET media but did not 
employ additional washing procedures of the cumulus mass. 
These groups achieved improved fertilization rates but 
neither achieved any pregnancies. All but one fertilized 
ovum in these studies underwent cleavage. 
The relative value and effects on fertilization rate of 
fetal cord and donor serum are somewhat difficult to assess 
from these cases. However, replacement of antibody- 
containing serum in IVF/ET media with antibody-negative 
serum appears to improve fertilization. The combination of 
washing the ova and eliminating patient serum from IVF/ET 
media would be expected to improve the chances of concep- 
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tion. On the basis of this limited data, IVF/ET seems to be 
a suitable treatment for women with antisperm antibodies. 
However, since IVF/ET is a major undertaking for an infer¬ 
tile couple, the therapeutic value of IVF/ET, particularly 
with these two modifications, must be tested further. 
For couples with autoimmunity to sperm in the male 
undergoing IVF/ET, pregnancies were achieved in the current 
study without any apparent modification of methodology, and 
have similarly been reported by Naaktgeboren et al^5 and 
Clarke et al^6 (table 7). However, Clarke does not indicate 
whether cryopreserved semen collected and frozen during 
previous prednisone therapy was used for the patients who 
achieved pregnancies. Clarke did report poor fertilization 
rates in those men with _>80% of their sperm bound as 
compared with a normal fertilization and conception rate in 
IVF/ET for those men with <80% of their sperm bound. 
Further studies must evaluate possible in vitro manipula¬ 
tions of sperm in IVF/ET to reduce antisperm antibody 
binding, particularly in men with high levels of antisperm 
antibodies. Clearly, conception is possible in at least a 
subset of men with immunologic infertility by IVF/ET alone. 
The findings of the current study further define the 
relevance of antisperm antibodies in IVF/ET. Clinically 
significant antibodies to sperm were present in an unse¬ 
lected population undergoing IVF/ET, particularly in those 
patients whose infertility was unexplained. Antibodies to 
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sperm head in female serum and follicular fluid reduced 
fertilization in IVF/ET. Cleavage was also reduced in the 
presence of these antibodies in female serum. The immuno- 
bead binding assay proved to be an excellent detector of 
clinically significant antibodies, particularly because it 
determines the region of antibody binding to sperm. Using 
the immunobead binding assay, we were able to identify those 
patients with immunologic infertility which was clinically 
significant. 
Based on these findings, we will initiate clinical 
screening for antisperm antibodies at Yale among couples at 
high risk for immunologic infertility. Couples with either 
unexplained infertility or a history of impaired fertili¬ 
zation in a previous IVF/ET cycle will be tested with the 
immunobead binding assay for antisperm antibodies. Subse¬ 
quently, couples whose infertility is immunologic will have 
the opportunity to undergo IVF/ET with appropriate modifi¬ 
cations to maximize their chances of conception. 
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Figure 1 
Immunobead Binding to Sperm Head and Tail Tip 
immunobead 
binding 
Figure 1. Immunobeads (polyacrylamide beads with covalently 
bound rabbit antibodies to human IgA, IgG or IgM) bind 
immunoglobulin bound to the sperm plasma membrane. In the 
presence of antibody-bound sperm (as illustrated), immuno¬ 
beads are seen bound to sperm surface by phase contrast 
microscopy. In the absence of antibody-bound sperm, 
no immunobead binding occurs. 

Figure 2. Immunobead Binding to Sperm Head and Tail Tip 
(original magnification x200) 

Figure 3- Immunobead Binding to Sperm Head and Tail Tip 
(original magnification x200) 

Figure 4. No Immunobead Binding to Sperm 
(original magnification x200) 
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Figure 5 
Oocyte Fertilization Rates in the Presence vs. Absence 
of Antibodies to Sperm Head in Female Serum, 
Follicular Fluid, Semen, and Male Serum 
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Figure 5* Fertilization was significantly impaired in 
the presence of antibodies to sperm head in female 
serum. Fertilization was also impaired in the presence 
of antibodies to sperm head in follicular fluid. 
However, due to the small number of oocytes involved 
(only oocytes from traps of follicular fluid tested are 
reported), this difference is not statistically 
significant. There was no significant impairment of 
fertilization in the presence of these antibodies in 
semen or male serum. 
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Figure 6 
Oocyte Fertilization Rates in the Presence vs. Absence 
of Antibodies to Sperm Tail Tip in Female Serum, 
Follicular Fluid, Semen, and Male Serum 
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Figure 6.Oocyte fertilization was not significantly 
impaired in the presence of antibodies to sperm tail 
tip in any of the fluids tested. 
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Figure 7 
Zygote Cleavage Rate and Pregnancy Rate by IVF/ET 
in the Presence vs. Absence of Antibodies 
to Sperm Head in Female Serum 
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Figure 7.Zygote cleavage was impaired in the presence 
of antibodies to sperm head in female serum. Pregnancy 
was not significantly impaired in the presence of 
these antibodies in female serum. 
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Figure 8 
Incidence of Antibodies to Sperm Head in Couples 
with Unexplained Infertility vs. Tubal Infertility 
by Fluid Tested 
fluid tested 
Figure 8. Antibodies to sperm head were detected in 
a significantly higher proportion of patients with 
unexplained infertility than tubal infertility in 
each of the 4 fluids tested and in all 4 fluids 
combined. 
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Figure 9 
Distribution of Patients with Antibodies to 
Sperm Head in Female Serum 
in Unexplained vs. Tubal Infertility* 
unexplained 
inf ertility 
*p=0.08 (NS) 
Figure 9. The vast majority of patients with 
antibodies to sperm head in female serum had 
otherwise unexplained infertility. 
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Results of Immunobead Binding and IVF/ET By Couple Table 1 
IMMUNOBEAD BINDING RESULTS IVF/ET RESULTS 
Cp Head Tail tip Tail Fert. Cl . Pr . IVF 
# FS FF S MS FS FF S MS FS FF S MS # % # ind 
1 + + — - + + - + + + - 0/4 0 0/0 NP U 
2 + + - + - - - - - - 0/6 0 0/0 NP U 
3 + + - + + - + - _ _ - 0/2 0 0/0 NP U 
4 - - 0/6 0 0/0 NP U 
5 - 
- 0/1 0 0/0 NP T 
6 1/8 14 1/1 NP T 
7 
- 1/5 20 1/1 P M 
' 8 - 2/9 22 2/2 P U 
9 - - - + - - + - _ - 1/4 25 0/1 NP T 
10 - - 2/5 40 1/2 NP M 
11 + + - + + - - + - - 3/7 43 0/3 NP U 
12 - - - + - - - - _ _ - 1/2 50 1/1 NP T 
13 + + - - + - - - - _ - 3/5 60 3/3 NP T 
14 - - + - + - - - - - 5/8 63 4/5 NP T 
15 2/3 67 2/2 NP T 
16 + - _ - 2/3 67 2/2 P T 
17 - _ - - + - + - _ - 3/4 75 2/3 NP T 
18 3/4 75 3/3 NP U 
19 - - - + + - - - - - 6/8 75 6/6 NP T 
20 - - - - - + - - - 3/4 75 3/3 NP T 
21 - - - - - + - - - - 10/13 77 9/10 NP T 
22 - 7/9 78 7/7 P T 
23 - 6/7 86 6/6 NP T 
24 - - - + - - - - - - 6/7 86 5/6 P T 
25 - 7/8 88 6/7 NP T 
26 1/1 100 0/1 NP T 
27 - 7/7 100 6/7 P T 
28 1/1 100 1/1 NP U 
29 4/4 100 4/4 NP T 
30 2/2 100 2/2 P T 
31 8/8 100 8/8 NP M 
32 - - - + - - - - - - 5/5 100 5/5 NP M 
33 + + + + - + - + - - + 3/3 100 3/3 P U 
34 - + + - - + + - + + 5/5 100 5/5 NP T 
35 - - - - - - - + - - - 3/3 100 3/3 NP T 
36 - - - - - - + + - - - 2/2 100 1/2 NP T 
37 - - - - - - - + - - - 1/1 100 1/1 NP T 
38 - - - - + + - - - - - 5/5 100 5/5 NP U 
39 - — - - + + - - - - - 2/2 100 2/2 NF T 
40 3/3 100 3/3 NP T 
Cp #, couple number; FS, female serum; FF, follicular fluid; 
S, serum; MS, male serum; Fert., oocyte fertilization; 
Cl.#, # zygotes cleaved; Pr., pregnancy outcome; P, pregnant; 
NP, nonpregnant; IVF Ind., Indication for IVF/ET; 
T, tubal factor; U, unexplained infertility; M, male factor. 
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Table 2 
Incidence of Antisperm Antibodies in AO IVF'/ET Couples 
by Fluid and Region of Antibody Binding to Sperm 
Head 
No. (%) 
Tail tip 
No. (%) 
Tail 
No. (%) 
Female serum 6 (15) 12 (30) 2 (5) 
Follicular fluid 5 (13) 10 (25) 1 (3) 
Semen 3 (8) A (10) 1 (3) 
Male serum 3 (8) 12 (30) 2 (5) 
Table 3 
Distribution of Antisperm Antibodies 
by Isotype of Immunoglobulin for Each Fluid 
and Region of Binding to Sperm 
Head 
(No. ) 
Tail tip 
(No . ) 
Tail 
(No.) 
Female serum *A=1 
G = 1 
M= 1 
A , G = 2 
G , M=1 
A = 2 
M = 5 
A , G = 2 
A , M=2 
A,G,M=1 
G = 2 
Follicular 
fluid 
A = 1 
G = 2 
A , G = 2 
A = 3 
G= 1 
M=3 
A , G = 2 
A, M= 1 
G= 1 
Semen G = 2 
A , G= 1 
A= 1 
G= 1 
A , G = 2 
A , G= 1 
Male serum A= 1 
G = 2 
A = 3 
G = 1 
M = 3 
A , G = 2 
A, M= 1 
A,G,M=2 
G = 2 
* A =Ig A; G = I g G ; M = I g M . 

61 
Tests for Detection of Antisperm Antibodies Table 4 
Test Methodology Ad vantages Disadvantages 
Sperm 
Aggluti¬ 
nation 
Tests 
(TSAT/ 
GAT,65 
TAT66) 
Sperm agglutinate 
in presence of 
bivalent antibody 
bound to sperm 
surface 
(serum test) 
Widely 
available 
1.Not specific , 
i.e, clumping 
on nonimmune 
basis 
2 . Poor correla¬ 
tion with 
fertility 
status 
3.None except 
TAT localize 
Sperm 
Immo bi- 
1izing 
Tes 168 
(SIT) 
Antibody binding 
to sperm acti¬ 
vates complement 
system to cause 
sperm immobili¬ 
zation or cyto¬ 
toxicity 
(serum test) 
1.Specific 
2. Reproducible 
3. Widely 
available 
1.False nega¬ 
tives, i.e., 
won't detect 
antibodies 
that don't 
fix comple¬ 
ment or 
immobilize 
2 . Doesn't 
localize 
sperm binding 
Indirect 
Immuno¬ 
fluore¬ 
scence 
Tests69,70 
Fluorescence- 
labeled anti¬ 
globulins bind 
to antibodies 
bound to sperm 
prepared by 
fixation with 
methanol 
(serum test) 
1. Highly 
sensitive 
2. Determines 
region of 
sperm bound 
1. False posi¬ 
tives due to 
sperm inter¬ 
nal antigens 
exposed by 
fixation 
2. Poor correla¬ 
tion with 
fertility 
status 
Enzyme- 
Linked 
Immuno¬ 
sorbent 
A s sa y ^1-4 
(ELISA) 
Enzyme-linked 
antiglobulins 
bind antibody on 
sperm surface of 
whole sperm or 
sperm membrane 
extracts and 
substrate is 
added (semen , 
serum, biologic 
fluid test) 
Quantitative 1. False posi¬ 
tives and 
negatives due 
to denatura- 
tion of sperm 
membrane with 
f ixation 
2. Doesn ' t 
localize 
sperm binding 
(continued) 
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Detection of Antisperm Antibodies (continued) Table 4 
Tests Methodology Advantages Disadvantages 
Panning 
Assay 76 
Antibody-bound 
sperm stick to 
antiglobulin- 
coated wells 
(semen , serum 
biologic fluid 
test) 
Can be used 
on sperm with 
low motility 
1.Specificity , 
sensitivity 
unknown 
2. Qualitative 
3. Doesn't 
localize 
sperm binding 
Sperm- 
Cervical 
Mucus 
Contact 
T e s t ^ 7 
(SCMCT) 
Antisperm anti¬ 
bodies in semen 
or cervical mucus 
(CM) cause "sha¬ 
king** reaction 
when sperm con¬ 
tact CM (CM, 
(semen test) 
Can detect 
antibodies 
in cervical 
mucus or 
semen 
1 .Specificity, 
sensitivity 
unknown 
2.Qualitative 
3 . D o e s n ' t 
localize 
sperm binding 
Radio- 
labeled 
Anti¬ 
globulin 
Assay6 
Radiolabeled 
antiglobulin 
bind to anti¬ 
bodies bound 
to sperm 
(semen, serum, 
biologic fluid 
test) 
1.Highly 
sensitive 
2.Specific 
3. Quantitative 
4. Determines 
Ig isotype 
1.Doesn't 
determine 
region of 
sperm bound 
Mixed 
Agglu¬ 
tination 
Reaction 
(MAR)80 
Mixed agglutina¬ 
tion of sperm & 
sensitized Rh+ 
RBCs occurs 
when RBCs are 
mixed with semen 
and anti-IgG 
anti-serum 
(semen test) 
1.Specific 
2.Can detect 
antibodies 
bound to 
sperm in 
semen 
1.Sensitivity 
unknown 
2 . Qualitative 
3. Can only 
detect IgG 
4. Region of 
s perm bound 
difficult to 
determine 
Immuno bead 
Binding 
Testsl'>31 
(IBA) 
Immunobeads with 
bound antiglobu¬ 
lin molecules 
bind antibodies 
bound to sperm 
surface (semen, 
serum, biologic 
fluid test) 
1.Specific 
2. Localizes 
region of 
sperm bound 
3. Determines 
proportion 
of ejaculate 
that's anti- 
body-bound 
4 . Determines 
Ig isotype 
1.Sensitivity 
unknown 
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Table 5 
Sites Where Antisperm Antibodies Might Impair Reproduction 
Spermatogenesis Autoimmunity may lead to aspermato¬ 
genesis, oligospermatogenesis or 
abnormal sperm morphology. 
Sperm Transport Immunoglobulins in semen, cervical 
mucus or female reproductive tract 
fluids may bind sperm surface and 
decrease sperm motility or impair 
sperm penetration of cervical mucus. 
Sperm Survival Antibody binding of sperm may lead to 
lysis of antibody-coated sperm by 
complement components or enhance 
macrophage phagocytosis of sperm in 
the reproductive tract through 
binding of the Fc portion of antisperm 
antibody to the macrophage Fc receptor. 
Gamete Interaction Antisperm antibodies may impair sperm 
capacitation, the acrosome reaction, 
sperm binding or penetration of the 
zona pellucida, sperm-ova fusion or 
zygote cleavage. 
Embryo Survival Antisperm antibodies may react with 
antigenic determinants on the embryo 
and block implantation or lead to 
spontaneous abortion after 
implantation. 
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Reports of IVF/ET Outcomes in Females with Table 6 
Immunologic Infertility 
Authors 
Immunol. 
Findings 
# 
Cps 
Total 
# IVF 
Cy c . 
Total 
Fert . 
(no.) 
Total 
Preg. 
( no . ) 
Special IVF 
Methods 
Used 
Ackerman 
e t a 12 1 
+GAT & +SIT 
in female 
serum 1 2 2/7 1 TM 
1 )Cumulus 
washed free 
of foil, 
fluid x 4 
2)Human fetal 
cord serum 
used in medic 
Yovich 
e t a 12 2 
>1: +GAT, 
+TSAT,+SIT 
in female 
serum 5 7 26/32 2 TM 
1) Cumulus 
washed free 
of foil, 
fluid x 3 
2) Donor serum 
used in medic 
Clarke + TAT & + SIT; 
+IBA in 
female serum 
|& foil . 
i fluid 1 
3 
4 6/16 0 
Type of serun 
in media; 
Patient serun 
2 4/8 0 Donor serum 
3 11/14 0 Human fetal 
cord serum 
Kamada 
et al23 
+SIT in 
female serum 1 
1 0/2 0 
Type of serun 
in media: 
Patient serun 
1 3/3 1 
Human fetal 
cord serum 
Mandel- 
baum 
e t a 1 
+IBA in 
female serum 
and foil, 
fluid: 
to sperm head 6 6 9/27 1 
None 
to sperm 
tail tip 12 12 32/55 1 
Immunol., immunologic; Cps, couples; Cyc., cycles; 
Fert., fertilization; Preg., pregnancies; foil, fluid, 
follicular fluid; TM, term. 

Reports of IVF/ET Outcomes in Males with 
Immunolgic Infertility 
Table 7 
Authors 
Immunol. 
Findings 1 
# 
1 p s 
Total 
# IVF 
Cyc . 
Total 
Fert. 
(no. ) 
Total 
Pr eg . 
( no . ) 
Special IVF 
Methods 
Used 
Clarke 
et al26 
+SIT in male 
serum & +IBA 
in semen 
a)>80% sperm 
IgA-bound 
17 
12 27/100 0 
Cryopreserved 
semen f rom 
previous 
prednisolone 
Rx used in 
7/17 patients b)<80% sperm 
IgA-bound 
18 47/65 2 SAB 
2 TM 
Naakt- 
geboren 
et al25 
+TAT in male 
serum & +MAR 
in semen 
1 2 5/6 1 
SAB 
None 
Mandel- 
baum 
et al 
+IBA in semen: 
to sperm head 3 3 8/14 1 
None 
to sperm 
tail tip 4 4 20/24 0 
+IBA in male 
serum: 
to sperm head 3 3 13/16 1 
to sperm 
tail tip 12 12 24/43 3 
Immunol., immunologic; Cps, couples; Fert. , fertilization; 
Preg., pregnancies; foil, fluid; follicular fluid; TM=term; 
SAB=spontaneous abortion 
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